Medical Pharmacology: ANS Adrenergic Pharmacology

Medical Pharmacology Question Bank: ANS Adrenergic Pharmacology — Module 5 | Core Concepts

Chapter 5: Autonomic Adrenergic Pharmacology — Module 5: Adrenergic Antagonists — Alpha Blockers
Core Concepts: Foundational Knowledge (12 Questions)

BEFORE YOU BEGIN

Modules 1 through 4 covered the agonist side of adrenergic pharmacology — drugs that activate receptors, directly or indirectly. Module 5 introduces the antagonists: drugs that occupy adrenergic receptors without activating them, blocking the effects of endogenous catecholamines and exogenous agonists. The alpha blockers are a clinically diverse group whose applications range from hypertension and benign prostatic hyperplasia to pheochromocytoma management and the reversal of vasopressor overdose. Their pharmacology introduces important concepts — the difference between reversible and irreversible antagonism, the first-dose effect, epinephrine reversal, and the critical sequencing rule in pheochromocytoma — that have direct patient safety implications. The receptor subtype framework from Module 1 is essential here: understanding which alpha subtype is blocked and where determines everything about what a drug does clinically.

1. Alpha-1 adrenergic receptor antagonists block the postsynaptic alpha-1 receptors on vascular smooth muscle. Which of the following correctly describes the primary pharmacological consequence of alpha-1 blockade and identifies the compensatory physiological response it triggers?

A) Alpha-1 blockade prevents norepinephrine from activating Gq-coupled receptors on vascular smooth muscle, abolishing the IP3/DAG/calcium cascade that produces vasoconstriction; because alpha-1 receptors also mediate cardiac inotropy, alpha-1 blockade simultaneously reduces contractility and heart rate, producing combined vasodilation and negative chronotropy without any compensatory reflex
B) Alpha-1 blockade prevents vasoconstriction by blocking the Gq/PLC/IP3/calcium pathway in vascular smooth muscle, producing vasodilation and a fall in systemic vascular resistance (SVR); the resulting drop in blood pressure activates arterial baroreceptors, which increase sympathetic outflow and vagal withdrawal — producing a reflex tachycardia; alpha-1 blockers do not block cardiac beta-1 receptors, so the reflex tachycardia is unopposed, making it a clinically significant side effect particularly with non-selective alpha blockers
C) Alpha-1 blockade produces vasodilation by blocking the Gq/PLC/IP3/calcium pathway in vascular smooth muscle, reducing SVR and blood pressure; the fall in blood pressure activates baroreceptors, increasing sympathetic outflow and producing reflex tachycardia; alpha-1 receptors are also present on the urethral sphincter and prostate smooth muscle, so alpha-1 blockade simultaneously relaxes these structures — explaining the use of selective alpha-1 antagonists in benign prostatic hyperplasia (BPH)
D) Alpha-1 blockade selectively dilates venous capacitance vessels without affecting arterial resistance, producing venous pooling and a reduction in cardiac preload; the reduced cardiac preload lowers cardiac output through the Frank-Starling mechanism; no compensatory tachycardia occurs because alpha-1 receptors are not involved in baroreceptor reflex signaling
E) Alpha-1 blockade prevents NE from activating postsynaptic receptors, causing compensatory NE accumulation in the synaptic cleft; the excess synaptic NE spills over and activates presynaptic alpha-2 autoreceptors, amplifying the negative feedback and further reducing sympathetic tone; the net cardiovascular effect is profound bradycardia rather than tachycardia

ANSWER: C

Rationale:

Alpha-1 adrenergic receptors on vascular smooth muscle are Gq-coupled — their activation by NE triggers PLC, generating IP3 and DAG, raising intracellular calcium, activating MLCK, and producing vasoconstriction. Alpha-1 antagonists (prazosin, terazosin, doxazosin, phentolamine) block this receptor, preventing vasoconstriction, reducing SVR, and lowering blood pressure. The fall in MAP activates arterial baroreceptors (carotid sinus, aortic arch), which increase sympathetic efferent firing and reduce vagal tone — producing reflex tachycardia. Because alpha-1 blockers do not block cardiac beta-1 receptors, the reflex sympathetic activation increases heart rate through beta-1-mediated chronotropy unopposed. Option C is most complete because it correctly adds the clinically important alpha-1 presence in the lower urinary tract (urethral sphincter, prostate, bladder neck) — where alpha-1 blockade produces smooth muscle relaxation that reduces outflow obstruction, explaining why selective alpha-1 antagonists (tamsulosin, alfuzosin, silodosin) are first-line therapy for BPH.

Option A: Option A incorrectly states that alpha-1 blockade reduces heart rate and contractility. Alpha-1 receptors are not the primary mediators of cardiac chronotropy or inotropy (beta-1 receptors mediate these); alpha-1 blockade produces vasodilation with reflex tachycardia, not bradycardia.
Option B: Option B is partially correct in describing alpha-1 blockade's mechanism (Gq/PLC/IP3/calcium pathway inhibition producing vasodilation and SVR reduction) and reflex tachycardia; however, Option C is the correct answer because it provides the most clinically complete account — specifically explaining that alpha-1 blockade in the prostate and bladder neck (smooth muscle relaxation reducing outflow obstruction) is the basis for the use of selective alpha-1 antagonists in BPH, which is a clinically essential pharmacological application not captured in Option B.
Option D: Option D incorrectly states that alpha-1 blockade selectively dilates venous capacitance vessels without affecting arterial resistance. Alpha-1 receptors are present on both arteriolar and venous smooth muscle; alpha-1 blockade reduces both arterial resistance and venous tone, and reflex tachycardia does occur.
Option E: Option E incorrectly describes the compensatory response as profound bradycardia from alpha-2 autoreceptor activation. The dominant compensatory response to alpha-1 blockade-induced hypotension is baroreceptor-mediated reflex tachycardia, not bradycardia.

2. Prazosin is a selective alpha-1 adrenergic antagonist used in hypertension. A patient takes her first dose of prazosin 1 mg at bedtime and wakes at 3 AM with severe dizziness and near-syncope when she gets up to use the bathroom. Her blood pressure while supine is 118/72 mmHg but drops to 78/48 mmHg upon standing. Which of the following best explains this clinical presentation using alpha blocker pharmacology?

A) The first-dose effect of prazosin — characterized by profound orthostatic hypotension occurring after the initial dose — results from the sudden unmasking of alpha-1-mediated vasoconstriction in both arterial and venous smooth muscle without prior compensatory adaptation; on standing, gravity-dependent venous pooling in the lower extremities normally triggers a rapid alpha-1-mediated venoconstriction to maintain venous return; prazosin blocks this response, leading to a dramatic reduction in cardiac preload and output that is not immediately compensated; subsequent doses produce less orthostatic hypotension because reflex sympathetic upregulation and volume redistribution develop over days of therapy
B) The presentation reflects prazosin's direct cardiac effects — prazosin blocks beta-1 receptors in the SA node at first-dose concentrations, producing bradycardia that reduces cardiac output to levels insufficient to maintain blood pressure on standing; after several doses, beta-1 receptor desensitization reduces this effect
C) The presentation reflects prazosin's inhibition of the baroreceptor reflex — prazosin crosses the blood-brain barrier and blocks alpha-1 receptors in the nucleus tractus solitarius, impairing the central component of the baroreceptor reflex and preventing the normal heart rate and vasoconstriction response to standing
D) The orthostatic drop reflects prazosin's selective action on venous capacitance vessels only — prazosin dilates veins but not arteries; the resulting venous pooling reduces cardiac preload on standing without any arterial vasodilation; subsequent doses are equally hypotensive because the venous mechanism does not develop tolerance
E) The presentation reflects prazosin's irreversible alpha-1 receptor blockade — the first dose permanently occupies all alpha-1 receptors, and recovery requires receptor resynthesis over weeks; subsequent doses are less hypotensive only because new alpha-1 receptors have been synthesized in the interval between doses

ANSWER: A

Rationale:

The first-dose effect is a well-characterized adverse effect of prazosin and related selective alpha-1 antagonists, most pronounced with the initial dose and when taken in the upright position. The mechanism relates to the dual role of alpha-1 receptors in maintaining blood pressure: (1) Arteriolar alpha-1 receptors maintain peripheral vascular resistance — blocking them reduces SVR; (2) Venous alpha-1 receptors mediate venoconstriction — blocking them impairs the normal gravity-dependent venoconstriction that occurs on standing, allowing venous pooling in the lower extremities, reducing venous return, reducing cardiac filling (preload), and consequently reducing cardiac output. The combined arterial and venous alpha-1 blockade produces a severe orthostatic drop on standing, especially after the first dose when compensatory adaptations (plasma volume expansion, receptor downregulation of the reflex arc) have not yet developed. Clinical management: start prazosin at the lowest dose (1 mg) at bedtime to minimize first-dose syncope risk; titrate slowly upward.

Option B: Option B incorrectly attributes the presentation to beta-1 receptor blockade. Prazosin is a selective alpha-1 antagonist with no significant beta-1 blocking activity; it does not produce bradycardia.
Option C: Option C incorrectly attributes the presentation to central baroreceptor reflex impairment via CNS alpha-1 blockade. Prazosin's hypotensive effect is peripheral (vascular smooth muscle alpha-1 blockade), not central.
Option D: Option D incorrectly states prazosin acts selectively on venous capacitance vessels and does not produce arterial vasodilation. Prazosin blocks alpha-1 receptors on both arteriolar and venous smooth muscle; arterial vasodilation and SVR reduction are prominent effects.
Option E: Option E incorrectly describes prazosin as an irreversible alpha-1 blocker requiring receptor resynthesis. Prazosin is a competitive reversible antagonist; it does not permanently occupy alpha-1 receptors. Phenoxybenzamine is the irreversible alpha blocker.

3. Phenoxybenzamine and phentolamine are both non-selective alpha blockers (blocking both alpha-1 and alpha-2 receptors), but they differ critically in the reversibility of their receptor blockade. Which of the following correctly distinguishes these two drugs and identifies the clinical implication of this difference?

A) Phenoxybenzamine and phentolamine are both reversible competitive antagonists, but phenoxybenzamine has a much longer duration of action because it is more slowly dissociated from the receptor; the clinical implication is that phenoxybenzamine requires less frequent dosing but produces the same qualitative type of alpha blockade as phentolamine
B) Phentolamine is irreversible and phenoxybenzamine is reversible; phentolamine's irreversible blockade is exploited in pheochromocytoma preoperative preparation because it cannot be overcome by the massive catecholamine surges during tumor manipulation; phenoxybenzamine's reversible blockade is preferred for diagnostic alpha blockade tests because it can be rapidly reversed
C) Phenoxybenzamine and phentolamine both block alpha-1 receptors selectively; the distinction between them is that phenoxybenzamine also blocks beta-1 receptors while phentolamine does not; this makes phenoxybenzamine a combined alpha-beta blocker similar to carvedilol and labetalol, producing less reflex tachycardia than phentolamine
D) Phenoxybenzamine is an irreversible covalent alpha blocker — it forms a covalent bond with alpha-1 and alpha-2 receptors, producing blockade that cannot be overcome by increasing agonist concentration and that persists until new receptor protein is synthesized (days); phentolamine is a reversible competitive antagonist whose blockade can be overcome by high concentrations of NE or epinephrine; in pheochromocytoma surgery, phenoxybenzamine is preferred for preoperative alpha blockade because its irreversible blockade cannot be surmounted by the massive catecholamine surges that occur during tumor manipulation, while phentolamine given IV is used for acute intraoperative hypertensive episodes because its short duration allows rapid titration
E) Phenoxybenzamine is a selective alpha-1 blocker while phentolamine is a selective alpha-2 blocker; their non-selective classification is a historical error corrected in current pharmacology; phenoxybenzamine's alpha-1 selectivity explains its use in BPH, similar to prazosin and tamsulosin

ANSWER: D

Rationale:

The irreversibility of phenoxybenzamine is its defining pharmacological property and the basis for its specific clinical role. Phenoxybenzamine forms a stable covalent bond with alpha receptors (both alpha-1 and alpha-2), producing non-competitive (insurmountable) blockade — increasing NE or epinephrine concentration cannot overcome the blockade because the drug is chemically bonded to the receptor. Recovery requires synthesis of new receptor protein, taking 24–48 hours. Phentolamine is a reversible competitive antagonist — its blockade can be surmounted by sufficiently high agonist concentrations. In pheochromocytoma surgery, tumor manipulation releases massive catecholamine surges; only irreversible blockade (phenoxybenzamine, given orally for 1–2 weeks preoperatively) can reliably prevent the resulting hypertensive crisis, because reversible blockade would be overwhelmed by the catecholamine surge. Phentolamine, given IV, is useful for acute intraoperative hypertensive spikes where rapid onset and short duration allow precise titration. Both drugs block alpha-1 and alpha-2 (non-selective), with the alpha-2 blockade contributing to reflex tachycardia by removing presynaptic NE feedback inhibition.

Option A: Option A incorrectly states both drugs are reversible. Phenoxybenzamine is irreversible (covalent); phentolamine is reversible. The distinction is pharmacologically and clinically fundamental.
Option B: Option B reverses the reversibility — incorrectly stating phentolamine is irreversible and phenoxybenzamine is reversible. The correct assignment is phenoxybenzamine = irreversible, phentolamine = reversible.
Option C: Option C incorrectly states both drugs are selective alpha-1 blockers and that phenoxybenzamine also blocks beta-1 receptors. Both are non-selective alpha blockers (alpha-1 and alpha-2); neither is a beta blocker.
Option E: Option E incorrectly states phenoxybenzamine is selective alpha-1 and phentolamine is selective alpha-2. Both are non-selective, blocking both alpha-1 and alpha-2 receptors. Selective alpha-1 blockers are a different drug class (prazosin, terazosin, doxazosin, tamsulosin).

4. Tamsulosin is a selective alpha-1A adrenergic antagonist used specifically for benign prostatic hyperplasia (BPH — enlargement of the prostate gland that obstructs urine flow). Which of the following correctly explains tamsulosin's mechanism of action in BPH and identifies its pharmacological advantage over non-selective alpha-1 antagonists such as prazosin?

A) Tamsulosin selectively blocks beta-2 receptors in the bladder detrusor muscle, producing detrusor relaxation and reducing bladder outlet pressure; this reduces urinary urgency and improves flow without affecting vascular tone; prazosin lacks this beta-2 selectivity and therefore has no effect on bladder function
B) Tamsulosin selectively blocks alpha-1A adrenergic receptors — the predominant subtype in prostatic smooth muscle, bladder neck, and urethral sphincter — producing relaxation of these structures and reducing the dynamic component of bladder outlet obstruction; because alpha-1A receptors are less prevalent in vascular smooth muscle (where alpha-1B is predominant), tamsulosin produces less vasodilation and less orthostatic hypotension than prazosin; this subtype selectivity allows effective urinary symptom relief with a more favorable cardiovascular side effect profile
C) Tamsulosin blocks alpha-1A receptors in the prostate and simultaneously activates beta-3 receptors in the bladder detrusor, producing a dual mechanism of urinary obstruction relief; prazosin lacks the beta-3 agonist component and is therefore less effective than tamsulosin in relieving BPH symptoms
D) Tamsulosin blocks alpha-1 receptors non-selectively throughout the urinary tract, producing complete relaxation of the prostate, bladder neck, and urethral sphincter; its advantage over prazosin is pharmacokinetic rather than pharmacodynamic — tamsulosin has a longer half-life allowing once-daily dosing, while prazosin requires multiple daily doses; both drugs produce equivalent orthostatic hypotension
E) Tamsulosin selectively blocks alpha-2 receptors in the prostate rather than alpha-1 receptors; alpha-2 receptors in prostatic smooth muscle mediate contraction through Gi-mediated calcium release; blocking these receptors produces prostatic smooth muscle relaxation; prazosin blocks alpha-1 receptors which are less abundant in the prostate, explaining its inferior efficacy in BPH

ANSWER: B

Rationale:

The prostate gland, bladder neck, and proximal urethra are richly supplied with alpha-1A adrenergic receptors, whose activation by endogenous NE produces smooth muscle contraction that contributes to bladder outlet obstruction in BPH. Tamsulosin selectively blocks alpha-1A receptors, relaxing prostatic and urethral smooth muscle and reducing the dynamic (smooth muscle tone) component of outlet obstruction — improving urine flow rate and reducing symptoms (urgency, hesitancy, incomplete emptying). The pharmacological advantage over non-selective alpha-1 blockers is subtype selectivity: vascular smooth muscle expresses predominantly alpha-1B receptors (with some alpha-1A). Tamsulosin's alpha-1A preference means it produces significantly less vascular alpha-1B blockade, resulting in less vasodilation, less reduction in SVR, and substantially less orthostatic hypotension than prazosin or terazosin — which block alpha-1A and alpha-1B equally. This favorable cardiovascular profile makes tamsulosin preferred for BPH in patients where orthostatic hypotension is a concern (elderly patients, antihypertensive polypharmacy).

Option A: Option A incorrectly identifies tamsulosin as a beta-2 blocker acting on the detrusor. Tamsulosin is an alpha-1A antagonist acting on prostatic and urethral smooth muscle, not a beta receptor agent.
Option C: Option C incorrectly adds beta-3 agonist activity to tamsulosin's mechanism. Tamsulosin is a selective alpha-1A antagonist only; it has no beta-3 agonist activity. Mirabegron is the beta-3 agonist used for bladder conditions.
Option D: Option D incorrectly describes tamsulosin as non-selective and attributes its advantage solely to pharmacokinetics. Tamsulosin's advantage is pharmacodynamic (alpha-1A subtype selectivity reducing vascular side effects), not merely pharmacokinetic. Prazosin also has a shorter half-life, but that is secondary to the subtype selectivity distinction.
Option E: Option E incorrectly identifies tamsulosin as an alpha-2 blocker and incorrectly states prostatic alpha-2 receptors mediate contraction via Gi-mediated calcium. Prostatic smooth muscle contraction is mediated by alpha-1A receptors (Gq-coupled); tamsulosin blocks alpha-1A, not alpha-2 receptors.

5. In a patient with pheochromocytoma (a catecholamine-secreting adrenal medullary tumor) undergoing surgical resection, the anesthesiologist must block the effects of massive catecholamine surges released during tumor manipulation. The surgeon asks why alpha blockade must be established before beta blockade in this patient. Which of the following best explains this sequencing requirement?

A) Alpha blockade must precede beta blockade because beta blockers administered first would directly stimulate the pheochromocytoma to release more catecholamines through a beta receptor-mediated positive feedback loop on the tumor; alpha blockade eliminates this feedback before beta blockade is safe
B) Alpha blockade must precede beta blockade because beta blockers in this setting are rapidly metabolized by the tumor's elevated catecholamine environment; without prior alpha blockade to reduce the catecholamine burden, beta blockers are pharmacologically ineffective and cannot produce the intended heart rate control
C) Alpha blockade must precede beta blockade because in pheochromocytoma, the excessive circulating catecholamines produce intense alpha-1-mediated vasoconstriction maintaining blood pressure despite potentially reduced cardiac output; if a beta blocker is given first, it reduces cardiac output (by blocking beta-1 inotropy and chronotropy) while the intense alpha-1 vasoconstriction remains unopposed — producing a severe reduction in cardiac output against a fixed high-resistance circuit, which can precipitate cardiovascular collapse; alpha blockade first reduces vascular resistance, so that when beta blockade is then added to control heart rate and arrhythmias, the cardiac output reduction is not working against an unrelieved high-SVR state
D) Alpha blockade must precede beta blockade because beta blockers selectively dilate the adrenal medullary blood supply through beta-2-mediated vasodilation, increasing blood flow to the tumor and amplifying catecholamine release; alpha blockade first constricts the adrenal blood supply, reducing tumor perfusion before beta blockade is added
E) The sequencing requirement is a historical convention without a pharmacological basis — both alpha and beta blockade can be established simultaneously or in either order; the recommendation to alpha-block first simply reflects the observation that alpha blockers have a longer onset of action and must be given first to achieve blockade before the beta blocker takes effect

ANSWER: C

Rationale:

The sequencing rule — alpha blockade before beta blockade in pheochromocytoma — is one of the most clinically important safety principles in adrenergic pharmacology, and its rationale is precisely as described in Option C. In pheochromocytoma, excessive circulating catecholamines (NE and epinephrine) produce intense alpha-1-mediated vasoconstriction throughout the systemic vasculature, maintaining blood pressure despite the physiological stress of the tumor. The cardiac effects of catecholamines (beta-1-mediated tachycardia and increased contractility) are often part of the clinical presentation. If a beta blocker is administered first, beta-1 blockade reduces cardiac output by slowing heart rate and reducing contractility. However, the intense alpha-1 vasoconstriction (high SVR) is not relieved — the heart is now trying to pump against an unrelieved high-resistance vascular circuit while its output has been pharmacologically reduced. This combination — low cardiac output against high SVR — can produce a catastrophic fall in tissue perfusion and cardiovascular collapse. Establishing alpha blockade first reduces SVR, creating a lower-resistance circuit. Once SVR is reduced, adding beta blockade to control tachycardia and arrhythmias is safe because the heart's reduced output is now working against a lower vascular resistance.

Option A: Option A incorrectly attributes the sequencing requirement to beta receptors on the tumor stimulating catecholamine release. Beta receptors on the pheochromocytoma do not mediate a positive feedback loop for catecholamine release that is pharmacologically relevant to this sequencing rule.
Option B: Option B incorrectly attributes beta blocker ineffectiveness to metabolic inactivation by catecholamines. Beta blockers are not metabolized by catecholamines; the sequencing rule is based on hemodynamic physiology, not pharmacokinetics.
Option D: Option D incorrectly describes beta-2-mediated dilation of the adrenal blood supply by beta blockers amplifying tumor catecholamine release. This mechanism does not exist; beta blockers do not selectively vasodilate the adrenal medullary supply in a clinically relevant manner.
Option E: Option E incorrectly dismisses the sequencing rule as a historical convention without pharmacological basis. The alpha-before-beta sequencing rule has a rigorous pharmacodynamic rationale — preventing cardiovascular collapse from low cardiac output against unrelieved high SVR — and is a patient safety imperative, not a convention.

6. Non-selective alpha blockers (phentolamine, phenoxybenzamine) that block both alpha-1 and alpha-2 receptors tend to produce more pronounced reflex tachycardia than selective alpha-1 blockers (prazosin, tamsulosin). Using presynaptic receptor pharmacology, which of the following best explains this difference?

A) Non-selective alpha blockers produce more tachycardia because they also block cardiac beta-1 receptors, activating a compensatory reflex that overshoots and paradoxically increases heart rate rather than slowing it; selective alpha-1 blockers do not affect beta-1 receptors and therefore do not trigger this paradoxical reflex
B) Non-selective alpha blockers produce more tachycardia because they block alpha-2 receptors in the sinoatrial node, directly removing the inhibitory alpha-2-mediated brake on pacemaker firing; this direct SA node alpha-2 blockade combines with the baroreceptor reflex tachycardia from vasodilation to produce a greater total heart rate increase
C) Non-selective alpha blockers produce more reflex tachycardia than selective alpha-1 blockers because non-selective blockade includes presynaptic alpha-2 autoreceptors on sympathetic nerve terminals — normally when NE is released and blood pressure falls, NE activates presynaptic alpha-2 receptors to reduce further NE release (negative feedback); blocking presynaptic alpha-2 removes this brake, allowing the baroreceptor reflex-driven increase in sympathetic firing to release more NE per impulse — amplifying both the vasodilatory NE surge at other receptor types and the cardiac beta-1-mediated tachycardia; selective alpha-1 blockers leave presynaptic alpha-2 intact, so NE release per sympathetic impulse is self-limited
D) Non-selective alpha blockers produce more tachycardia because they block alpha-2 receptors in the carotid sinus, impairing baroreceptor mechanosensing; with an impaired baroreceptor, any blood pressure change produces an exaggerated sympathetic response including more tachycardia; selective alpha-1 blockers do not reach the carotid sinus alpha-2 receptors and therefore do not impair baroreceptor sensitivity
E) Non-selective alpha blockers produce less tachycardia than selective alpha-1 blockers — the non-selective classification is a marketing error; in clinical trials, phentolamine and phenoxybenzamine consistently produce lower heart rates than prazosin and tamsulosin because the alpha-2 blockade provides central sympatholysis that counteracts the baroreceptor-driven tachycardia

ANSWER: C

Rationale:

The greater reflex tachycardia with non-selective alpha blockers is explained by their additional blockade of presynaptic alpha-2 autoreceptors. When blood pressure falls from alpha-1 blockade, the baroreceptor reflex increases sympathetic firing to sympathetic nerve terminals supplying the heart and vasculature. Normally, the released NE activates presynaptic alpha-2 autoreceptors on the same terminals, providing negative feedback that limits further NE release per impulse — a self-dampening mechanism. With a non-selective alpha blocker (phentolamine, phenoxybenzamine), this presynaptic alpha-2 feedback is also blocked — the sympathetic nerve terminals have lost their self-limiting brake; each sympathetic impulse now releases more NE than it would otherwise, amplifying both the cardiac beta-1-mediated chronotropic response and the overall sympathetic activation. Selective alpha-1 blockers (prazosin) leave presynaptic alpha-2 autoreceptors intact, so the self-limiting NE feedback mechanism is preserved, and reflex tachycardia is less pronounced. This pharmacological difference is one reason why selective alpha-1 blockers are preferred in clinical practice.

Option A: Option A incorrectly attributes the greater tachycardia to beta-1 receptor blockade by non-selective alpha blockers. Alpha blockers (selective or non-selective) do not block beta-1 receptors; reflex tachycardia from alpha blockade is mediated through the baroreceptor reflex and beta-1-mediated chronotropy, not direct beta-1 blockade.
Option B: Option B incorrectly attributes the greater tachycardia to direct SA node alpha-2 blockade. While alpha-2 receptors exist in cardiac tissue, the dominant mechanism of greater tachycardia with non-selective blockers is removal of the presynaptic autoreceptor brake on NE release at sympathetic terminals, not direct SA node alpha-2 blockade.
Option D: Option D incorrectly attributes the difference to carotid sinus alpha-2 receptor blockade impairing baroreceptor mechanosensing. Alpha-2 receptors in the carotid sinus are not the established mechanism for the differential tachycardia between selective and non-selective alpha blockers.
Option E: Option E incorrectly states that non-selective alpha blockers produce less tachycardia than selective alpha-1 blockers. The opposite is true — non-selective blockers, by removing the presynaptic alpha-2 brake on NE release, produce greater reflex tachycardia.

7. "Epinephrine reversal" is a classic pharmacological demonstration in which the normal pressor response to epinephrine is converted to a depressor response after alpha blockade. Which of the following best explains the mechanism of epinephrine reversal using alpha receptor subtype pharmacology?

A) After alpha blockade with a non-selective alpha blocker, intravenous epinephrine no longer raises blood pressure but instead lowers it — because epinephrine's alpha-1-mediated vasoconstriction is blocked, leaving only its beta-2-mediated vasodilation (in skeletal muscle vasculature) and beta-1-mediated cardiac stimulation; the net effect of unopposed beta-2-mediated vasodilation is a fall in systemic vascular resistance and blood pressure, despite increased cardiac output — the directional shift from pressor to depressor response demonstrates that epinephrine's normal pressor effect depends on alpha-1 activation
B) After alpha blockade, epinephrine reversal occurs because the alpha blocker has converted epinephrine from an agonist to an inverse agonist at beta receptors; the epinephrine-alpha blocker complex has negative intrinsic efficacy at beta receptors, producing vasodilation by actively reducing basal beta receptor tone below resting levels
C) Epinephrine reversal occurs because alpha blockers also block beta-2 receptors at the doses used in this demonstration; without beta-2-mediated vasodilation normally counteracted by alpha-1 vasoconstriction, the remaining beta-1 cardiac stimulation produces a paradoxical blood pressure fall through baroreflex-mediated peripheral vasodilation
D) Epinephrine reversal occurs because after alpha blockade, epinephrine is metabolized to a different active compound by MAO; this metabolite is a pure beta blocker that converts the pressor response to a depressor response; the name "reversal" reflects the metabolic conversion rather than receptor pharmacology
E) Epinephrine reversal demonstrates that alpha-1 receptors mediate all of epinephrine's cardiovascular effects; after alpha blockade, epinephrine has no remaining cardiovascular activity at all — blood pressure returns to pre-epinephrine baseline; the apparent "depressor" response is simply removal of the pressor effect rather than a true blood pressure reduction below baseline

ANSWER: A

Rationale:

Epinephrine reversal is one of the most elegant demonstrations in receptor pharmacology and directly illustrates the concept of receptor subtype-dependent net pharmacological effect. Epinephrine normally activates alpha-1, alpha-2, beta-1, and beta-2 receptors. The dominant cardiovascular effect at standard doses includes alpha-1-mediated vasoconstriction (raising SVR) that overcomes the concurrent beta-2-mediated vasodilation in skeletal muscle — producing a net pressor response. After pretreatment with a non-selective alpha blocker (phentolamine, phenoxybenzamine), alpha-1 receptor blockade prevents epinephrine from producing vasoconstriction. Epinephrine's remaining active receptor effects are beta-1 (positive inotropy and chronotropy — increasing cardiac output) and beta-2 (vasodilation in skeletal muscle vasculature — reducing SVR). With alpha-1 blockade, beta-2-mediated vasodilation is now unopposed — SVR falls, and despite the increased cardiac output from beta-1 stimulation, the net blood pressure effect is a fall. The demonstration proves that epinephrine's normal pressor response depends on alpha-1 activation; without it, the beta-2 vasodilatory effect predominates.

Option B: Option B incorrectly describes epinephrine as becoming an inverse agonist at beta receptors after alpha blockade. Inverse agonism is an intrinsic property of the drug-receptor interaction, not something created by co-administration of an alpha blocker; epinephrine remains a full beta agonist after alpha blockade.
Option C: Option C incorrectly states that alpha blockers also block beta-2 receptors at the doses used. Alpha blockers are selective for alpha receptors; they do not block beta receptors. The mechanism of reversal is not beta-2 blockade.
Option D: Option D incorrectly attributes epinephrine reversal to MAO-mediated metabolism of epinephrine to a beta blocker compound. Epinephrine is metabolized by COMT and MAO to inactive compounds, not to beta blockers; the reversal is a receptor pharmacology phenomenon, not a metabolic one.
Option E: Option E incorrectly states that after alpha blockade, epinephrine has no remaining cardiovascular activity and blood pressure simply returns to baseline. Epinephrine retains its beta-1 and beta-2 receptor activities after alpha blockade; the blood pressure falls below baseline (not just to baseline) because unopposed beta-2 vasodilation actively reduces SVR below pre-epinephrine levels.

8. A 62-year-old man with pheochromocytoma has been prepared for surgery with phenoxybenzamine 20 mg twice daily for 14 days. In the operating room during tumor manipulation, his blood pressure spikes to 240/130 mmHg. The anesthesiologist administers phentolamine 5 mg IV. Within 2 minutes his blood pressure falls to 148/88 mmHg. Using the pharmacology of these two alpha blockers, which of the following best explains why phentolamine — not phenoxybenzamine — is used for acute intraoperative blood pressure control?

A) Phentolamine is used acutely because it blocks beta-1 receptors in addition to alpha receptors, combining vasodilation (alpha blockade) with heart rate reduction (beta-1 blockade) — a dual mechanism that provides faster and more complete blood pressure control than phenoxybenzamine alone; phenoxybenzamine lacks beta receptor activity
B) Phentolamine is used acutely because it has a higher affinity for alpha-1 receptors than phenoxybenzamine, producing more complete alpha-1 blockade at lower doses; the higher affinity makes it more effective against the massive catecholamine surge during tumor manipulation
C) Phentolamine is used acutely because it also activates imidazoline I1 receptors in the brainstem, adding a central sympatholytic component that synergizes with peripheral alpha blockade to produce faster blood pressure reduction; phenoxybenzamine lacks imidazoline receptor activity
D) Phentolamine is used for acute intraoperative blood pressure control because it is a reversible competitive alpha blocker with rapid IV onset and short duration (10–15 minutes), allowing precise titration of blood pressure during surgery; phenoxybenzamine has already been used for preoperative alpha blockade to provide a stable baseline, but its irreversible, long-lasting blockade makes it unsuitable for rapid titration of acute hypertensive spikes — adding more phenoxybenzamine cannot be reversed if blood pressure drops too far; phentolamine's reversibility and brief duration make it the ideal agent for moment-to-moment intraoperative pressure management
E) Phentolamine is used acutely because it penetrates the blood-brain barrier and blocks central alpha-1 receptors responsible for the hypertensive surge from tumor manipulation; phenoxybenzamine does not cross the BBB and therefore only provides peripheral alpha blockade

ANSWER: D

Rationale:

The complementary use of phenoxybenzamine (preoperative, irreversible) and phentolamine (intraoperative, reversible) in pheochromocytoma surgery exemplifies the clinical importance of understanding drug reversibility. Phenoxybenzamine is given for 1–2 weeks preoperatively to establish sustained, irreversible alpha blockade that cannot be overcome by catecholamine surges — providing hemodynamic stability and allowing volume repletion. However, its irreversibility is a liability for acute intraoperative management: once administered, its effect cannot be titrated or reversed if blood pressure drops below the desired range. Phentolamine, by contrast, is a reversible competitive antagonist with rapid IV onset (1–2 minutes) and short duration of action (10–15 minutes). Administered as an IV bolus or infusion, phentolamine allows the anesthesiologist to precisely titrate blood pressure responses to surgical stimuli — if pressure drops too far, stopping the infusion allows phentolamine's effect to wane and blood pressure to recover within minutes. This combination — long-acting irreversible baseline blockade (phenoxybenzamine) with short-acting titratable blockade (phentolamine) for acute spikes — is a pharmacologically rational strategy exploiting the different reversibility profiles of two non-selective alpha blockers.

Option A: Option A incorrectly states that phentolamine blocks beta-1 receptors. Phentolamine is an alpha blocker with no significant beta receptor antagonism; it does not reduce heart rate through beta-1 blockade. The advantage of phentolamine over phenoxybenzamine is reversibility and duration, not beta blockade.
Option B: Option B incorrectly attributes phentolamine's use to higher alpha-1 affinity. Phentolamine is used for acute control because of its reversibility and short duration, not because of greater alpha receptor affinity.
Option C: Option C incorrectly attributes a central sympatholytic component to phentolamine via imidazoline receptor activation. Phentolamine's mechanism is peripheral alpha receptor blockade; it does not have established central imidazoline receptor activity relevant to its clinical use in this setting.
Option E: Option E incorrectly attributes phentolamine's effectiveness to CNS penetration and central alpha-1 blockade. Phentolamine acts peripherally on vascular smooth muscle alpha receptors; its advantage over phenoxybenzamine in the acute setting is reversibility and short duration, not CNS penetration.

9. A 45-year-old woman is started on doxazosin for hypertension. After 6 weeks of therapy her blood pressure is well controlled. She reports that she was told she should avoid over-the-counter medications containing pseudoephedrine. Her pharmacist explains that pseudoephedrine interacts unfavorably with her medication. Which of the following best explains this interaction using adrenergic receptor pharmacology?

A) Pseudoephedrine blocks NET (the norepinephrine transporter) at sympathetic nerve terminals, preventing doxazosin reuptake after it is released into the synapse; this pharmacokinetic interaction increases doxazosin plasma concentrations to toxic levels, producing excessive alpha-1 blockade and life-threatening orthostatic hypotension
B) Pseudoephedrine, as a mixed-acting sympathomimetic, releases NE from nerve terminals and has direct alpha-1 agonist activity; in a patient taking an alpha-1 blocker like doxazosin, pseudoephedrine's NE-releasing indirect component still exerts effects at alpha-2, beta-1, and beta-2 receptors that are not blocked by doxazosin — producing tachycardia (beta-1), bronchodilation (beta-2), and increased NE release (alpha-2 blockade being absent) — but its alpha-1-mediated vasoconstriction (the intended decongestant effect) is blocked by doxazosin; the net interaction is that pseudoephedrine's cardiovascular side effects (tachycardia, palpitations) may be unmasked without its vasopressor counterbalance, making the combination less safe and less effective as a decongestant
C) Pseudoephedrine's direct alpha-1 agonist activity at nasal mucosal alpha-1 receptors is completely blocked by doxazosin, eliminating any decongestant benefit; additionally, pseudoephedrine's sympathomimetic cardiovascular effects (tachycardia from beta-1 activation, blood pressure elevation from NE release) are not blocked by doxazosin and may partially overcome doxazosin's antihypertensive effect; the combination is unfavorable but not dangerous at standard OTC doses
D) Pseudoephedrine is safely combined with doxazosin because doxazosin's alpha-1 blockade prevents pseudoephedrine from raising blood pressure; any NE released by pseudoephedrine cannot activate blocked alpha-1 receptors, so the vasopressor side effect of pseudoephedrine is pharmacologically neutralized; only the beneficial decongestant effect at nasal mucosal alpha-1 receptors remains, and the combination is therefore therapeutically advantageous
E) Pseudoephedrine interacts with doxazosin by inhibiting its renal tubular secretion; doxazosin is eliminated by active tubular secretion and pseudoephedrine competitively inhibits the same transporter; doxazosin accumulates to toxic concentrations, producing severe and prolonged alpha-1 blockade with life-threatening hypotension; the interaction is pharmacokinetic, not pharmacodynamic

ANSWER: B

Rationale:

This interaction question requires applying alpha-1 blocker pharmacology to a clinically common scenario. Doxazosin is a selective alpha-1 antagonist — it blocks alpha-1 receptors on vascular smooth muscle and in the urogenital tract but does not block alpha-2, beta-1, or beta-2 receptors. Pseudoephedrine is a mixed-acting sympathomimetic — it enters nerve terminals via NET to release NE (indirect mechanism) and also has modest direct alpha-1 and beta agonist activity. In a patient taking doxazosin: (1) The decongestant mechanism — alpha-1-mediated vasoconstriction of nasal mucosal vessels — is blocked by doxazosin, reducing pseudoephedrine's effectiveness as a decongestant; (2) Beta-1-mediated cardiac effects (tachycardia, palpitations) are not blocked and may be unmasked; (3) The released NE can compete with doxazosin at alpha-1 receptors, partially overcoming the antihypertensive effect at high pseudoephedrine concentrations; (4) The net result is cardiovascular side effects (tachycardia) without the vasopressor counterbalance, and potentially reduced blood pressure control.

Option A: Option A incorrectly describes pseudoephedrine as a NET blocker that prevents doxazosin reuptake. Pseudoephedrine is a NET substrate (it is transported into terminals via NET); it does not block NET. Additionally, doxazosin is not taken up by NET — it is not a monoamine.
Option C: Option C is incorrect: pseudoephedrine's mechanism is indirect sympathomimetic (NE release) rather than direct alpha-1 agonism, so it is not "completely blocked" by doxazosin in the same way a direct alpha-1 agonist would be; however, the more important clinical error is the claim that pseudoephedrine's effects are entirely blocked — pseudoephedrine also has direct adrenergic receptor activity and some of its systemic effects persist through NET-mediated mechanisms even with alpha-1 receptor blockade; additionally, pseudoephedrine in an MAOI-treated patient risks hypertensive crisis through a different mechanism entirely.
Option D: Option D incorrectly states the combination is therapeutically advantageous and that only the decongestant effect remains. In fact, doxazosin blocks the decongestant effect (alpha-1 in nasal mucosa) while leaving the cardiovascular side effects unblocked — the opposite of the conclusion in
Option E: Option E incorrectly attributes the interaction to pharmacokinetic renal tubular secretion competition. Doxazosin is primarily metabolized hepatically, not by active renal tubular secretion; the pseudoephedrine-doxazosin interaction is pharmacodynamic (receptor-level), not pharmacokinetic.

10. A 78-year-old man with a 10-year history of BPH is taking tamsulosin 0.4 mg daily. He is scheduled for cataract surgery. His ophthalmologist notes in the preoperative assessment that the patient is taking tamsulosin and immediately raises a safety concern. Which of the following best identifies this concern and explains its pharmacological basis?

A) The concern is that tamsulosin causes significant intraoperative hypertension — alpha-1A blockade in the iris dilator muscle prevents pupillary dilation during surgery; without adequate mydriasis, the operative field is inadequate and the blood pressure rises reflexively from the physiological stress of inadequate anesthesia
B) The concern is drug-drug interaction between tamsulosin and the mydriatic agents used in cataract surgery — tamsulosin inhibits CYP3A4, increasing plasma concentrations of phenylephrine eye drops used for pupillary dilation, causing systemic hypertension and cardiac arrhythmias from phenylephrine toxicity
C) The concern is systemic absorption of topical ophthalmic phenylephrine — tamsulosin blocks peripheral alpha-1 receptors, and systemically absorbed phenylephrine (used for pupillary dilation) cannot produce vasoconstriction at blocked alpha-1 receptors, causing unopposed beta-mediated effects including severe tachycardia
D) The concern is intraoperative floppy iris syndrome (IFIS) — tamsulosin's alpha-1A blockade relaxes the iris dilator muscle (which contains alpha-1A receptors that normally maintain iris rigidity and pupillary dilation); during cataract surgery, the intraoperative floppy iris may billow, prolapse through surgical incisions, and constrict despite mydriatic drops — complicating the surgery and increasing the risk of complications; IFIS can occur even if tamsulosin was discontinued weeks or months before surgery, because the iris changes may be partially irreversible
E) The concern is postoperative vision loss — tamsulosin's alpha-1A blockade in the retinal vasculature reduces choroidal blood flow during and after cataract surgery, increasing the risk of ischemic optic neuropathy; patients on tamsulosin require prophylactic high-dose corticosteroids to protect retinal blood flow during the perioperative period

ANSWER: D

Rationale:

The ophthalmologist's concern is intraoperative floppy iris syndrome (IFIS) — a well-characterized complication of cataract surgery in patients taking alpha-1A antagonists (tamsulosin most commonly, but also other alpha-1 blockers). The iris dilator muscle contains alpha-1A adrenergic receptors whose activation by NE and epinephrine maintains iris tone and pupillary dilation. Tamsulosin blocks these receptors, producing flaccidity (floppiness) of the iris stroma. During cataract surgery, which requires a maximally dilated, rigid pupil for safe phacoemulsification and lens insertion, a floppy iris billows in response to intraoperative fluid currents, may prolapse through surgical incisions, and constricts progressively despite mydriatic drops — creating a narrow, mobile operative field. This dramatically increases surgical difficulty and the risk of iris trauma, posterior capsule rupture, and vitreous loss. Critically, IFIS can occur in patients who discontinued tamsulosin weeks to months before surgery, suggesting partial irreversibility of the iris changes. Ophthalmologists now routinely ask about alpha-1 blocker use before cataract surgery and use modified surgical techniques (intracameral mydriatics, iris expansion devices, dispersive viscoelastics) to manage IFIS when it is anticipated.

Option A: Option A incorrectly describes the concern as tamsulosin causing intraoperative hypertension from inadequate mydriasis and reflexive stress response. IFIS is the concern — the issue is surgical difficulty from a floppy iris, not hypertension.
Option B: Option B incorrectly attributes the concern to a CYP3A4 drug interaction between tamsulosin and phenylephrine eye drops causing systemic hypertension. Tamsulosin is not a significant CYP3A4 inhibitor, and the topical phenylephrine interaction with tamsulosin is not the established concern.
Option C: Option C incorrectly describes the concern as systemic absorption of phenylephrine causing tachycardia due to alpha-1 blockade. While systemic absorption of ophthalmic phenylephrine is possible, this is not the specific concern the ophthalmologist identifies regarding tamsulosin.
Option E: Option E incorrectly identifies the concern as postoperative vision loss from tamsulosin-induced retinal ischemia. Tamsulosin does not cause retinal vascular alpha-1A blockade-mediated ischemic optic neuropathy; IFIS is the recognized tamsulosin-cataract surgery interaction.

11. A 55-year-old man with hypertension and BPH is taking lisinopril (an ACE inhibitor) and is started on doxazosin for additional blood pressure control and urinary symptom relief. Two weeks later he presents to clinic with complaints of dizziness and one episode of near-fainting when rising from a chair. His supine blood pressure is 128/76 mmHg and his standing blood pressure is 96/58 mmHg. Which of the following best explains the pharmacological basis for this orthostatic hypotension and identifies the most appropriate management?

A) The orthostatic hypotension results from doxazosin's alpha-1 blockade in venous smooth muscle impairing the venoconstriction normally required to maintain venous return on standing, combined with lisinopril's reduction of angiotensin II-mediated aldosterone release reducing plasma volume — two complementary mechanisms that together produce a more profound orthostatic drop than either drug alone; management options include dose reduction of doxazosin, timing the doxazosin dose at bedtime to reduce peak-effect orthostatic risk, ensuring adequate hydration, advising the patient to rise slowly, and considering whether both antihypertensive effects are needed simultaneously
B) The orthostatic hypotension results exclusively from lisinopril — ACE inhibitors are the primary cause of orthostatic hypotension in hypertensive patients; doxazosin does not cause orthostatic hypotension at standard doses because its alpha-1A selectivity limits vascular effects; management is dose reduction of lisinopril
C) The orthostatic hypotension is caused by doxazosin activating presynaptic alpha-2 receptors through a paradoxical agonist effect at high plasma concentrations, reducing sympathetic NE release and impairing the normal vasoconstrictor response to standing; lisinopril is not contributing; management is switching from doxazosin to tamsulosin, which has less paradoxical alpha-2 agonist activity
D) The orthostatic hypotension results from doxazosin's direct cardiac beta-1 blocking effect reducing heart rate and preventing the compensatory tachycardia that normally maintains cardiac output during standing; lisinopril's renal effects reduce preload through natriuresis; management is adding a beta-1 agonist to restore heart rate response
E) The orthostatic hypotension is a first-dose effect of doxazosin occurring at two weeks — all alpha-1 blockers produce first-dose orthostatic hypotension only during the first 24 hours; a presentation at two weeks indicates a separate etiology unrelated to doxazosin; further investigation for autonomic neuropathy is required before attributing the hypotension to medications

ANSWER: A

Rationale:

This case illustrates pharmacodynamic drug interaction producing orthostatic hypotension. Two mechanisms operate in parallel: (1) Doxazosin (alpha-1 blocker) prevents alpha-1-mediated venoconstriction on standing — the normal reflex that reduces venous pooling in the lower extremities and maintains venous return and cardiac preload when gravity challenges the circulation. Without this venoconstriction, venous return falls on standing, reducing cardiac output and blood pressure. (2) Lisinopril (ACE inhibitor) reduces angiotensin II, which in turn reduces aldosterone secretion — aldosterone normally promotes sodium and water retention; reduced aldosterone causes a modest plasma volume reduction; reduced plasma volume decreases the reserve available to maintain cardiac filling when venous return is impaired by standing. The two mechanisms are pharmacodynamically additive — together producing a more profound orthostatic drop than either drug alone. Management focuses on minimizing the orthostatic risk: timing doxazosin at bedtime (reducing peak-effect upright activity), ensuring adequate hydration, advising slow position changes, and possibly dose reduction if symptoms persist.

Option B: Option B incorrectly attributes the hypotension exclusively to lisinopril and incorrectly states that doxazosin at standard doses does not cause orthostatic hypotension. Doxazosin is a well-established cause of orthostatic hypotension through alpha-1 venoconstriction blockade; alpha-1A selectivity of tamsulosin reduces this risk, but doxazosin is not subtype-selective.
Option C: Option C incorrectly describes doxazosin as having a paradoxical alpha-2 agonist effect at high concentrations. Doxazosin is a selective alpha-1 antagonist with no established alpha-2 agonist activity. Switching to tamsulosin would reduce orthostatic hypotension risk due to its alpha-1A selectivity, but the mechanism described is pharmacologically incorrect.
Option D: Option D incorrectly attributes the hypotension to doxazosin having direct beta-1 blocking activity. Doxazosin is a selective alpha-1 blocker with no beta receptor antagonism; it does not reduce heart rate through beta-1 blockade.
Option E: Option E incorrectly states that first-dose orthostatic hypotension occurs only in the first 24 hours and that a two-week presentation requires a separate etiology. While first-dose effect is most pronounced initially, orthostatic hypotension from alpha-1 blockade can persist and is a recognized adverse effect of ongoing doxazosin therapy, not limited to the first day.

12. Having completed Module 5, a student asks: "What is the unifying clinical pharmacology principle that connects the use of alpha blockers in hypertension, BPH, pheochromocytoma, and the prevention of IFIS?" Which of the following best captures this unifying principle?

A) The unifying principle is receptor subtype selectivity — all clinical applications of alpha blockers require drugs with the highest possible alpha-1A selectivity; non-selective blockers (phentolamine, phenoxybenzamine) are obsolete and no longer used clinically; the future of alpha blocker pharmacology is entirely in alpha-1A selective agents
B) The unifying principle is that all alpha blocker applications exploit blockade of alpha-1 (and sometimes alpha-2) adrenergic receptors in a tissue-specific manner — hypertension exploits alpha-1 vascular blockade to reduce SVR; BPH exploits alpha-1A blockade in prostatic and urethral smooth muscle to reduce outlet obstruction; pheochromocytoma management exploits irreversible alpha blockade to protect against catecholamine surges; IFIS results from unintended alpha-1A blockade in the iris dilator — in each case, the clinical outcome (intended or unintended) follows directly from alpha receptor blockade in a specific tissue; understanding which tissue expresses which alpha receptor subtype allows prediction of both therapeutic benefit and adverse effect in every clinical context
C) The unifying principle is dose-dependence — at low doses, alpha blockers selectively block alpha-1A receptors (producing BPH benefit without cardiovascular effects); at intermediate doses, they block alpha-1B (adding antihypertensive effect); at high doses, they block alpha-2 (adding the presynaptic feedback abolition and reflex tachycardia); IFIS occurs only at the highest doses when iris alpha-1A receptors are reached; dose titration determines the clinical application
D) The unifying principle is irreversibility — all clinically effective alpha blocker applications require irreversible receptor blockade to withstand catecholamine competition; reversible alpha blockers (prazosin, doxazosin, tamsulosin, phentolamine) are pharmacologically inferior to irreversible blockers (phenoxybenzamine) in all clinical settings; reversible blockers are used only when phenoxybenzamine is unavailable
E) The unifying principle is that alpha blockers must always be combined with beta blockers to be clinically effective — alpha blockade alone produces reflex tachycardia that counteracts the antihypertensive benefit; all alpha blocker clinical applications (hypertension, BPH, pheochromocytoma) require concurrent beta blockade to achieve clinical benefit; the adverse effects of alpha blockers (IFIS, orthostatic hypotension) are also mitigated by beta blockade

ANSWER: B

Rationale:

The unifying principle connecting all clinical applications of alpha blockers — hypertension, BPH, pheochromocytoma, and IFIS — is that each application reflects alpha receptor blockade in a tissue-specific anatomical location, with the clinical outcome (therapeutic or adverse) determined entirely by which tissue expresses the blocked receptor subtype. In hypertension: blocking alpha-1 receptors in vascular smooth muscle reduces SVR and lowers blood pressure. In BPH: blocking alpha-1A receptors in prostatic smooth muscle, bladder neck, and urethra reduces outlet obstruction and improves urine flow. In pheochromocytoma: irreversible blockade of alpha-1 (and alpha-2) receptors throughout the vascular system prevents catecholamine surges from producing hypertensive crises. In IFIS: the iris dilator muscle's alpha-1A receptors, blocked by tamsulosin, produce iris flaccidity — an unintended consequence of the same receptor subtype blockade that is therapeutically exploited in BPH. The same receptor pharmacology, the same drug, the same receptor subtype — different tissue locations produce both intended benefits and unintended adverse effects. This is the receptor-subtype-tissue-expression principle that runs through all of adrenergic pharmacology.

Option A: Option A incorrectly states that all clinical applications require the highest alpha-1A selectivity and that non-selective blockers are obsolete. Non-selective blockers (phenoxybenzamine, phentolamine) remain clinically essential in pheochromocytoma management precisely because of their non-selectivity and (for phenoxybenzamine) irreversibility.
Option C: Option C incorrectly attributes the different clinical applications to dose-dependent receptor subtype activation — low dose = alpha-1A, intermediate = alpha-1B, high = alpha-2. Alpha receptor subtype blockade is determined by drug structure and inherent selectivity, not dose titration through sequential receptor subtypes.
Option D: Option D incorrectly states that all effective alpha blocker applications require irreversible blockade and that reversible blockers are pharmacologically inferior. Reversible alpha-1 blockers (prazosin, doxazosin, tamsulosin) are first-line agents for hypertension and BPH with well-established efficacy; irreversible blockade (phenoxybenzamine) is specifically needed in pheochromocytoma, not universally superior.
Option E: Option E incorrectly states that alpha blockers must always be combined with beta blockers to be effective. Alpha blockers are used as monotherapy in hypertension and BPH; the requirement for beta blockade is specific to pheochromocytoma (added after alpha blockade is established) and is not a universal requirement for all alpha blocker applications.

BEFORE YOU MOVE ON

Module 5 has demonstrated that alpha receptor blockade, applied selectively or non-selectively, reversibly or irreversibly, to different tissue compartments, produces a coherent and predictable set of clinical outcomes — each explainable from receptor subtype pharmacology. The alpha blocker toolkit — selective alpha-1 (prazosin, doxazosin, tamsulosin) for hypertension and BPH; non-selective irreversible (phenoxybenzamine) for pheochromocytoma preoperative preparation; non-selective reversible (phentolamine) for acute intraoperative crises — represents pharmacological diversity in service of clinical precision. The first-dose effect, epinephrine reversal, the alpha-before-beta sequencing rule in pheochromocytoma, and IFIS are all predictable consequences of the receptor pharmacology you now understand. Module 6 completes Chapter 5 with the beta blockers — the most widely prescribed class of cardiovascular drugs — where the same receptor-tissue-outcome framework will reveal why cardioselective beta blockade, membrane-stabilizing activity, and intrinsic sympathomimetic activity each have distinct clinical relevance.